Butterfly NetworkFRA:7JA +1.63%40 EPS without NRI is €-0.26 as of Mar. 2026. GuruFocus rates FRA:7JA with a GF Score™ of 40/100 and a GF Value™ of €2.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Butterfly Network ranks better than 77.04% on this metric.
Butterfly Network's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.26.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 29.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 51.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Butterfly Network's EPS without NRI or its related term are showing as below:
FRA:7JA'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 27.5 Med: 45.8 Max: 70.8
Current: 29.9
During the past 7 years, Butterfly Network's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 70.80% per year. The lowest was 27.50% per year. And the median was 45.80% per year.
FRA:7JA's 3-Year EPS without NRI Growth Rate is ranked better than 77.04% of 662
companies
in the Medical Devices & Instruments industry
Industry Median: 8.15
vs FRA:7JA: 29.90
Butterfly Network's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.26.
Butterfly Network (FRA:7JA) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Butterfly Network EPS without NRI Related Terms
Butterfly Network EPS without NRI Historical Data
* Premium members only.
The historical data trend for Butterfly Network's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JA vs TMDX, AXGN, NEOG: EPS without NRI Comparison
For the Medical Devices subindustry, Butterfly Network's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Butterfly Network PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Butterfly Network's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Butterfly Network's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Butterfly Network (FRA:7JA) has a EPS without NRI of €-0.26 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Butterfly Network and its competitors. According to the industry distribution chart, Butterfly Network ranks #152 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 23%.
Is Butterfly Network's EPS without NRI too high?
Butterfly Network's current EPS without NRI is €-0.26. Based on the distribution chart, Butterfly Network ranks #152 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Butterfly Network has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Butterfly Network's EPS without NRI compare to TMDX and AXGN?
According to the Medical Devices & Instruments industry distribution chart, Butterfly Network ranks #152 out of 662 companies for EPS without NRI. This places Butterfly Network in the top 23% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Butterfly Network and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Butterfly Network's current EPS without NRI is €-0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Butterfly Network stock overvalued right now?
Based on GuruFocus' analysis, Butterfly Network (FRA:7JA) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.00, compared to a current price of €7.18 — trading 259% above its estimated fair value. The current EPS without NRI is €-0.26. Butterfly Network's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Butterfly Network (FRA:7JA), the current EPS without NRI is €-0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Butterfly Network (FRA:7JA) Overvalued in 2026?
Based on GuruFocus' analysis, Butterfly Network stock appears to be overvalued.
The current stock price of €7.18 is trading 259% above its estimated GF Value™ of €2.00.
GuruFocus considers Butterfly Network to be Significantly Overvalued.
Key valuation signals for FRA:7JA:
EPS without NRI: €-0.26
GF Value™: €2.00 vs. price of €7.18 (259% above fair value)
No single metric tells the full story. See the FRA:7JA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
40GF Score
Get the complete analysis for FRA:7JA
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JA has been successfully added to your 
